These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29121222)

  • 1. Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons.
    Bajaj NS; Patel N; Kalra R; Ahmad A; Venkatraman A; Arora G; Arora P
    Eur Heart J Qual Care Clin Outcomes; 2018 Apr; 4(2):132-141. PubMed ID: 29121222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.
    Hirsh Raccah B; Yanovsky A; Treves N; Rotshild V; Renoux C; Danenberg H; Eliaz R; Matok I
    Int J Cardiol; 2021 Jul; 335():7-14. PubMed ID: 33892045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.
    McDonagh M; Peterson K; Holzhammer B; Fazio S
    J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
    Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
    Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
    Cao YX; Liu HH; Dong QT; Li S; Li JJ
    Diabetes Obes Metab; 2018 Jun; 20(6):1391-1398. PubMed ID: 29377473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors.
    Choi HD; Kim JH
    Cardiovasc Ther; 2023; 2023():7362551. PubMed ID: 36704607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
    Guedeney P; Giustino G; Sorrentino S; Claessen BE; Camaj A; Kalkman DN; Vogel B; Sartori S; De Rosa S; Baber U; Indolfi C; Montalescot G; Dangas GD; Rosenson RS; Pocock SJ; Mehran R
    Eur Heart J; 2022 Feb; 43(7):e17-e25. PubMed ID: 31270529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
    Marston NA; Gurmu Y; Melloni GEM; Bonaca M; Gencer B; Sever PS; Pedersen TR; Keech AC; Roselli C; Lubitz SA; Ellinor PT; O'Donoghue ML; Giugliano RP; Ruff CT; Sabatine MS
    Circulation; 2020 May; 141(20):1600-1607. PubMed ID: 32223429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
    Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
    Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials.
    Dai H; Zhu Y; Chen Z; Yan R; Liu J; He Z; Zhang L; Zhang F; Yan S
    Endokrynol Pol; 2023; 74(3):234-242. PubMed ID: 37335067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.
    Gil-Núñez A; Masjuan J; Montaner J; Castellanos M; Segura T; Cardona P; Tembl JI; Purroy F; Arenillas J; Palacio E
    Neurologia (Engl Ed); 2022 Mar; 37(2):136-150. PubMed ID: 34906541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
    Karatasakis A; Danek BA; Karacsonyi J; Rangan BV; Roesle MK; Knickelbine T; Miedema MD; Khalili H; Ahmad Z; Abdullah S; Banerjee S; Brilakis ES
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29223954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Chen Q; Wu G; Li C; Qin X; Liu R; Zhang M
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):343-353. PubMed ID: 31823301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
    Gouni-Berthold I; Descamps OS; Fraass U; Hartfield E; Allcott K; Dent R; März W
    Br J Clin Pharmacol; 2016 Dec; 82(6):1412-1443. PubMed ID: 27478094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.